Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ethopropazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 4/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | BCHE | P06276 | 4/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | ACHE | P22303 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | ALOX12 | P18054 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.97 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.97 |
| ▸ | HTR1A | P08908 | 4/20 | 0.97 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.97 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethopropazine SCHEMBL123703 | 1.00 | ALDH1A1 (1.00) | ALDH1A1BCHEALOX15HSD17B10ACHE | |
| Ethopropazine SCHEMBL30516992 | 1.00 | ALDH1A1 (1.00) | ALDH1A1BCHEALOX15HSD17B10ACHE | |
| Ethopropazine SCHEMBL10616920 | 0.98 | ALDH1A1 (0.97) | ALDH1A1BCHEALOX15HSD17B10ACHE | |
| Ethopropazine SCHEMBL29426328 | 0.98 | CYP2D6 (1.00) | ALDH1A1BCHEALOX15HSD17B10ACHE | |
| Ethopropazine SCHEMBL34046 | 0.98 | CYP2D6 (1.00) | ALDH1A1BCHEALOX15HSD17B10ACHE | |
| Ethopropazine SCHEMBL34045 | 0.98 | CYP2D6 (1.00) | ALDH1A1BCHEALOX15HSD17B10ACHE | |
| Ethopropazine SCHEMBL10626220 | 0.97 | ALDH1A1 (0.94) | ALDH1A1BCHEALOX15HSD17B10ACHE | |
| Ethopropazine SCHEMBL2316087 | 0.97 | CYP2D6 (0.97) | ALDH1A1BCHEALOX15HSD17B10ACHE | |
| Ethopropazine SCHEMBL719170 | 0.95 | CYP2D6 (0.94) | ALDH1A1BCHEALOX15HSD17B10ACHE | |
| Ethopropazine SCHEMBL6943819 | 0.94 | ALDH1A1 (0.89) | ALDH1A1BCHEALOX15HSD17B10ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240122859-A1 | EXTENDED RELEASE MULTIPLE UNIT PELLET SYSTEM COMPOSITION AND ITS PROCESS FOR THE PREPARATION | NOKHA TRADING LLP (IN) | 2024-04-18 | — | — | US | claimed |
| EP-4232004-A1 | FRACTAL FORMULATIONS | Nanogyre Sprl (BE) | 2023-08-30 | — | — | EP | claimed |
| WO-2022172225-A1 | EXTENDED RELEASE MULTIPLE UNIT PELLET SYSTEM COMPOSITION AND ITS PROCESS FOR THE PREPARATION | LYRUS LIFE SCIENCES PVT. LTD. (IN) | 2022-08-18 | — | — | WO | claimed |
| WO-2021078412-A1 | FRACTAL FORMULATIONS | MESSADEK JALLAL (BE) | 2021-04-29 | — | — | WO | claimed |
| EP-3752137-A1 | REPURPOSING COMPOUNDS FOR THE TREATMENT OF INFECTIONS AND FOR MODULATING THE COMPOSITION OF THE GUT MICROBIOME | European Molecular Biology Laboratory (DE) | 2020-12-23 | — | — | EP | claimed |
| US-20200368218-A1 | REPURPOSING COMPOUNDS FOR THE TREATMENT OF INFECTIONS AND FOR MODULATING THE COMPOSITION OF THE GUT MICROBIOME | EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) | 2020-11-26 | — | — | US | claimed |
| US-20200147076-A1 | PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME | PLATFORM BRIGHTWORKS TWO, LTD. (US) | 2020-05-14 | — | — | US | claimed |
| WO-2019158559-A1 | REPURPOSING COMPOUNDS FOR THE TREATMENT OF INFECTIONS AND FOR MODULATING THE COMPOSITION OF THE GUT MICROBIOME | EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) | 2019-08-22 | — | — | WO | claimed |
| EP-3524237-A1 | REPURPOSING COMPOUNDS FOR THE TREATMENT OF INFECTIONS AND FOR MODULATING THE COMPOSITION OF THE GUT MICROBIOME | European Molecular Biology Laboratory (DE) | 2019-08-14 | — | — | EP | claimed |
| US-20190000862-A1 | METHODS AND SYSTEMS FOR THE DELIVERY OF A THERAPEUTIC AGENT | HANANJA EHF (IS) | 2019-01-03 | — | — | US | claimed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | claimed |
| WO-2000021504-A1 | ENCAPSULATION OF SENSITIVE LIQUID COMPONENTS INTO A MATRIX TO OBTAIN DISCRETE SHELF-STABLE PARTICLES | GENERAL MILLS, INC. (US) | 2000-04-20 | — | — | WO | claimed |
| EP-0935523-A4 | EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES | GEN MILLS INC (US) | 1999-12-29 | — | — | EP | claimed |
| EP-0935523-A1 | EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES | GENERAL MILLS, INC. (US) | 1999-08-18 | — | — | EP | claimed |
| WO-1998018610-A1 | EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES | LENGERICH BERNHARD H VAN (US) | 1998-05-07 | — | — | WO | claimed |
| EP-0743574-A2 | Migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| EP-0743573-A2 | Method for obtaining image contrast migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | claimed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | claimed |
| US-5192550-A | Dosage form for treating central nervous system disorders | ALZA CORPORATION (US) | 1993-03-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190000862-A1 | METHODS AND SYSTEMS FOR THE DELIVERY OF A THERAPEUTIC AGENT | TMEM205, NUP205, PIGS | CHRM1 2525/4885ALDH1A1 3463/4885BCHE 3155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.